Forget Altimmune: This Proven Obesity-Drug Giant Is the Better Weight-Loss Play [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
The weight-loss drug market has experienced incredible momentum over the past few years, and according to analyst projections, it hasn't peaked yet -- far from it. Among the many drugmakers looking to join this market is Altimmune (NASDAQ: ALT) , a smaller biotech whose shares could skyrocket from their current levels if its leading program is successful. While the upside potential of a company like Altimmune is attractive, it's important to highlight that there is plenty of risk, too. A safer -- and arguably better -- way to cash in on the anti-obesity drug market is to invest in a proven leader like Novo Nordisk (NYSE: NVO) . Let's find out more. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Image source: Getty Images. Both have faced challenges Altimmune and Novo Nordisk have both encountered headwin
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk Cuts Wegovy Prices in Half While Its Stock Sits Near a 52-Week Low [Yahoo! Finance]Yahoo! Finance
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVOPR Newswire
- PatentVest Releases New Report on The Oral Small-Molecule GLP-1 Patent Race [Yahoo! Finance]Yahoo! Finance
- Lilly's GLP-1 pill tops Novo's Rybelsus in head-to-head trial [Yahoo! Finance]Yahoo! Finance
- Walgreens Virtual Healthcare Adds Weight Management Services to Support Patients on Their Weight Loss Journey [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 2/23/26 - Form 6-K
- 2/23/26 - Form 6-K
- 2/20/26 - Form 6-K
- NVO's page on the SEC website